Dianthus Therapeutics, Inc.
Status: Publicly traded
Direct answer
Dianthus Therapeutics, Inc. is publicly traded on NASDAQ under the ticker DNTH.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid...
Can you invest in Dianthus Therapeutics, Inc.?
Yes. Dianthus Therapeutics, Inc. is publicly traded on NASDAQ under the ticker DNTH.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Dianthus Therapeutics, Inc.
Detailed equity research is provided by MarketSnap.